RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat blood cancer: targeted drug shows promise
Disease control OngoingThis study tests an experimental drug called zilovertamab vedotin in about 140 people whose diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. Re…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 04, 2026 16:29 UTC
-
Lymphoma combo drug trial pulled before it began
Disease control TerminatedThis study was designed to test the safety and effectiveness of combining the drug selinexor with other treatments for people whose diffuse large B-cell lymphoma had returned or stopped responding to therapy. It planned to enroll adults aged 18 and older who had already received …
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated May 04, 2026 16:20 UTC